ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026

ProMIS Neurosciences reported a net loss of $39.7 million for the year ended December 31, 2025 and held $6.1 million in cash at year-end, reflecting continued investment in its PRECISE-AD Phase 1b trial. The company completed enrollment of 144 participants in PRECISE-AD and closed a private placement in February 2026 for $75.5 million upfront proceeds, providing runway through 2027. Management expects a six-month blinded interim analysis in mid‑2026 and top-line 12‑month data in early 2027. Financial Highlights Net loss for year ended December 31, 2025: $39.7 million.Cash balance as of December 31, 2025: $6.1 million.Total current assets as of December 31, 2025: $9.18 million.Total current liabilities as of December 31, 2025: $10.41 million.Research and development expense for 2025: $33.38 million; general and administrative expense for 2025: $6.79 million. Business Highlights Completed enrollment of PRECISE-AD Phase 1b in December 2025 with 144 participants across three dosing cohorts (5, 10, 20 mg/kg).PMN310 continues to demonstrate a favorable safety profile with no treatment-related serious adverse events reported to date; DSMB recommended advancement to cohort 3 with no safety concerns.On track to complete six-month blinded interim assessments in Q2 2026 and to present the blinded interim analysis in early Q3 2026; full dosing expected by year-end 2026 and 12‑month top-line data anticipated in early 2027.Closed a transformational financing in February 2026 delivering $75.5 million upfront (up to $175 million including warrant exercise proceeds) to fund operations through 2027 and advance development, including a subcutaneous formulation of PMN310 and planning for a potential registrational study.Advancing preclinical programs: PMN267 (targeting TDP-43 for ALS/FTD) and PMN442 (targeting pathogenic alpha-synuclein for synucleinopathies) have been humanized and are in IND-enabling preparation.Original SEC Filing: ProMIS Neurosciences Inc. [ PMN ] - 8-K - Mar. 25, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.